Please assess the completion status of the following clinical trial:

Trial Title: Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative therapies do not exist. Eligible malignancies include:~  * Adenocarcinoma of the pancreas (locally advanced or metastatic)~ * Colorectal (stage IV)~ * Non-small cell lung (unresectable stage III or IV)~ * Relapsed ovarian or stage IV~ * Surgically unresectable or metastatic gastric adenocarcinoma~* First or second line therapy (within 4 weeks of initiating therapy).~* Minimum age 18 years~* Life expectancy of greater than 6 months~* ECOG Performance Status 0, 1, or 2 (Karnofsky 60% or greater).~* Participants must have normal organ and marrow function as outlined in the protocol.~Exclusion Criteria:~* Participants may not be receiving any other study agents.~* Known brain metastases should be excluded from this clinical trial because of their poor prognosis and higher potential for intracranial hemorrhage.~* Prior history of documented venous thromboembolic event or pulmonary embolism within the last 5 years years (excluding central line associated events whereby patients completed anticoagulation \> 3 months previously)~* Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)~* Any history of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to enoxaparin or heparin.~* History of heparin-induced thrombocytopenia~* Presence of coagulopathy (PT or PTT\> 1.5 x upper limit of normal)~* Familial bleeding diathesis~* Known diagnosis of disseminated intravascular coagulation~* Currently receiving anticoagulant therapy~* Current use of aspirin (\>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox), or regular use of non-steroidal anti-inflammatory agents more than twice weekly. Maximum dose of ibuprofen is 400mg no more than twice per week.~* Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High TFMP: Enoxaparin (Type: EXPERIMENTAL): Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).Only patients with high TFMP status at baseline were randomized to treatment or observation.
- High TFMP: Observation (Type: NO_INTERVENTION): Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.
- Low TFMP: Observation (Type: NO_INTERVENTION): Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).